甲磺酸阿帕替尼治疗晚期原发性肝癌的近期疗效及总生存期

Recent Curative Effect and Total Survival Time of Advanced Primary Liver Cancer Patients After Apatinib Therapy

目的：总结甲磺酸阿帕替尼治疗晚期原发性肝癌近期疗效及总生存期。方法：选取我院肿瘤科2015年12月至2016年11月间收治的72例原发性肝癌患者,根据不同治疗方式将其分为对照组和观察组,各36例,对照组患者给予最佳支持治疗及安慰剂治疗,观察组患者给予口服甲磺酸阿帕替尼治疗,比较两组患者的近期疗效、总生存期以及用药安全性。结果：观察组的客观缓解率（41.67%）明显高于对照组（19.44%）（χ^2=4.19,P=0.04）,疾病缓解率（58.33%）明显高于对照组（30.56%）（χ^2=5.63,P=0.02）;治疗后,观察组的平均生存期为（7.19±1.59）月,明显高于对照组（4.38±1.32）月（P〈0.05）;观察组与对照组的总不良反应发生率（86.11%、72.22%）及不良反应Ⅲ级、Ⅳ级发生率（30.56%、22.22%）比较均无明显差异（P〉0.05）。结论：甲磺酸阿帕替尼治疗晚期原发性肝癌可提高近期临床疗效,且与索拉菲尼相比无其他毒副作用,可延缓患者总生存期,建议推广使用。

Objective：To study the effect of apatinib methylate on the recent curative effect and total survival of advanced liver cancer.Methods：Seventy-two patients with primary liver cancer admitted to oncology department of our hospital from December 2015 to November 2016 were selected as the research objects.According to different treatment methods,they were divided into control group and observation group with 36 cases in each.Patients in the control group were given the best supportive care and placebo treatment,and patients in the observation group were given oral apatinib mesylate treatment,then,the short-term efficacy,overall survival and medication safety were compared between the two groups.Results：Objective remission rate of observation group（41.67%）was significantly higher than that in the control group（19.44%）（χ^2= 4.19,P=0.04）,and disease response rate（58.33%）was also significantly higher than the control group（30.56%）（χ^2=5.63,P=0.02）.After treatment,the mean survival time of the observation group was（7.19±1.59）months,which was significantly higher than that of the control group with（4.38±1.32）months（P〈0.05）.The incidences of adverse reactions（86.11% and72.22%）and gradeⅢ of adverse reactions（30.56% and 22.22%）in the observation group and the control group showed no significant differences（P〉0.05）.Conclusion：Apatinib mesylate treatment of primary advanced liver cancer can improve the short-term clinical efficacy and delay the overall survival of patients without other side effects.